Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans

Journal of Clinical Investigation

Volumn 119, Issue 1, 2009, Pages 225-236

  Aurora, Rajeev ^a   Donlin, Maureen J ^a   Cannon, Nathan A ^a   Tavis, John E ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Saint Louis University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS PROTEIN; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE SEQUENCE; GENETIC LINKAGE; GENETIC VARIABILITY; GENOME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYDROPHOBICITY; MALE; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL GENETICS; VIRUS ISOLATION; VIRUS RESISTANCE; AMINO ACID SEQUENCE; CLINICAL TRIAL; DRUG EFFECT; GENE REGULATORY NETWORK; GENETICS; MIDDLE AGED; MOLECULAR GENETICS; PREDICTION AND FORECASTING; VIRUS GENOME;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; GENE REGULATORY NETWORKS; GENETIC VARIATION; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 61749095537     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37085     Document Type: Article

References (56)

1. Armstrong, G.L., et al. 2006. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144:705-714.
2. Hadziyannis, S.J., et al. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355.
3. Manns, M.P., et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:958-965.
4. McHutchison, J.G., et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
5. Poynard, T., et al. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 352:1426-1432.
6. Davis, G.L., et al. 1998. Interferon alfa-2b alone or in combination with ribavirin for treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1493-1499.
7. Lemon, S.M., Walker, C., Alter, M.J., and Yi, M. 2007. Hepatitis C Virus. In Fields virology. D.M. Knipe, et al., editors. Lippincott, Williams & Wilkins. Philadelphia, Pennsylvania, USA. 1253-1304.
8. Lindenbach, B.D., and Rice, C.M. 2005. Unravelling hepatitis C virus replication from genome to function. Nature. 436:933-938.
9. Moradpour, D., Penin, F., and Rice, C.M. 2007. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5:453-463.
10. Gale, M., Jr., and Foy, E.M. 2005. Evasion of intracellular host defence by hepatitis C virus. Nature. 436:939-945.
11. Simmonds, P., et al. 1993. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74:2391-2399.
12. Bukh, J., Miller, R., and Purcell, R. 1995. Genetic heterogeneity of hepatitis c virus: quasispecies and genotypes. Semin. Liver Dis. 15:41-63.
13. Robertson, B., et al. 1998. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch. Virol. 143:2493-2503.
14. Simmonds, P. 2004. Genetic diversity and evolution of hepatitis C virus--15 years on. J. Gen. Virol. 85:3173-3188.
15. Fried, M.W., et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
16. Conjeevaram, H.S., et al. 2006. Peginterferon and ribavirin treatment in african american and caucasian american patients with hepatitis C genotype 1. Gastroenterology. 131:470-477.
17. Donlin, M.J., et al. 2007. Pretreatment sequence diversity differences in the full-length Hepatitis C Virus open reading frame correlate with early response to therapy. J. Virol. 81:8211-8224.
18. Cannon, N.A., Donlin, M.J., Fan, X., Aurora, R., and Tavis, J.E. 2008. Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS ONE. 3:e2123.
19. Eyal, E., Frenkel-Morgenstern, M., Sobolev, V., and Pietrokovski, S. 2007. A pair-to-pair amino acids substitution matrix and its applications for protein structure prediction. Proteins. 67:142-153.
20. Frenkel-Morgenstern, M., Magid, R., Eyal, E., and Pietrokovski, S. 2007. Refining intra-protein contact prediction by graph analysis. BMC Bioinformatics. 8(Suppl. 5):S6.
21. Gobel, U., Sander, C., Schneider, R., and Valencia, A. 1994. Correlated mutations and residue contacts in proteins. Proteins. 18:309-317.
22. Altschuh, D., Lesk, A.M., Bloomer, A.C., and Klug, A. 1987. Correlation of co-ordinated amino acid substitutions with function in viruses related to tobacco mosaic virus. J. Mol. Biol. 193:693-707.
23. Larson, S.M., Di Nardo, A.A., and Davidson, A.R. 2000. Analysis of covariation in an SH3 domain sequence alignment: applications in tertiary contact prediction and the design of compensating hydrophobic core substitutions. J. Mol. Biol. 303:433-446.
24. Olmea, O., Rost, B., and Valencia, A. 1999. Effective use of sequence correlation and conservation in fold recognition. J. Mol. Biol. 293:1221-1239.
25. Wang, Y.E., and DeLisi, C. 2006. Inferring protein-protein interactions in viral proteins by co-evolution of conserved side chains. Genome Inform. 17:23-35.
26. Lockless, S.W., and Ranganathan, R. 1999. Evolutionarily conserved pathways of energetic connectivity in protein families. Science. 286:295-299.
27. Suel, G.M., Lockless, S.W., Wall, M.A., and Ranganathan, R. 2003. Evolutionarily conserved networks of residues mediate allosteric communication in proteins. Nat. Struct. Biol. 10:59-69.
28. Lee, B.C., Park, K., and Kim, D. 2008. Analysis of the residue-residue coevolution network and the functionally important residues in proteins. Proteins. 72:863-872.
29. Kass, I., and Horovitz, A. 2002. Mapping pathways of allosteric communication in GroEL by analysis of correlated mutations. Proteins. 48:611-617.
30. Blight, K., and Norgard, E.A. 2006. HCV replicon systems. In Hepatitis C viruses: Genomes and molecular biology. S.L. Tan, editor. Horizon Bioscience. Wymondham, United Kingdom. 311-351.
31. Blight, K.J. 2007. Allelic variation in the hepatitis C virus NS4B protein dramatically influences RNA replication. J. Virol. 81:5724-5736.
32. Dustin, L.B., and Rice, C.M. 2007. Flying under the radar: the immunobiology of hepatitis C. Annu. Rev. Immunol. 25:71-99.
33. Barabasi, A.L. 2002. Linked: The new science of networks. Perseus Books Group. Cambridge, Massachusetts, USA. 256 pp.
34. Albert, R., and Barabasi, A.L. 2000. Topology of evolving networks: local events and universality. Phys. Rev. Lett. 85:5234-5237.
35. Zhou, D., et al. 2007. Separation of near full-length hepatitis C virus quasispecies variants from a complex population. J. Virol. Methods. 141:220-224.
36. Xu, Z., Fan, X., Xu, Y., and Di Bisceglie, A.M. 2008. Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a. J. Virol. 82:9417-9424.
37. Campo, D.S., Dimitrova, Z., Mitchell, R.J., Lara, J., and Khudyakov, Y. 2008. Coordinated evolution of the hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 105:9685-9690.
38. Lau, J.Y., Tam, R.C., Liang, T.J., and Hong, Z. 2002. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 35:1002-1009.
39. McHutchison, J.G., Bacon, B.R., and Owens, G.S. 2007. Making it happen: managed care considerations in vanquishing hepatitis C. Am. J. Manag. Care. 13(Suppl. 12):S327-S336.
40. Hahn, M.W., and Kern, A.D. 2005. Comparative genomics of centrality and essentiality in three eukaryotic protein-interaction networks. Mol. Biol. Evol. 22:803-806.
41. Ingolia, N.T. 2004. Topology and robustness in the Drosophila segment polarity network. PLoS Biol. 2:e123.
42. Wagner, A. 2000. Robustness against mutations in genetic networks of yeast. Nat. Genet. 24:355-361.
43. Yao, E., and Tavis, J.E. 2005. A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol. J. 2:88.
44. Jeanmougin, F., Thompson, J.D., Gouy, M., Higgins, D.G., and Gibson, T.J. 1998. Multiple sequence alignment with Clustal X. Trends Biochem. Sci. 23:403-405.
45. Atchley, W.R., Wollenberg, K.R., Fitch, W.M., Terhalle, W., and Dress, A.W. 2000. Correlations among amino acid sites in bHLH protein domains: an information theoretic analysis. Mol. Biol. Evol. 17:164-178.
46. Fodor, A.A., and Aldrich, R.W. 2004. Influence of conservation on calculations of amino acid covariance in multiple sequence alignments. Proteins. 56:211-221.
47. Shannon, P., et al. 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498-2504.
48. R. Development Core Team. 2004. A language and environment for statistical computing. The R Foundation for Statistical Computing. Vienna, Austria. http://www.r-project.org/.
49. Lee, B., and Richards, F.M. 1971. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55:379-400.
50. Aurora, R., Srinivasan, R., and Rose, G.D. 1994. Rules for alpha-helix termination by glycine. Science. 264:1126-1130.
51. Lesser, G.J., and Rose, G.D. 1990. Hydrophobicity of amino acid subgroups in proteins. Proteins. 8:6-13.
52. Kahsay, R.Y., Gao, G., and Liao, L. 2005. An improved hidden Markov model for transmembrane protein detection and topology prediction and its applications to complete genomes. Bioinformatics. 21:1853-1858.
53. Sonnhammer, E.L., von Heijne, G., and Krogh, A. 1998. A hidden Markov model for predicting trans-membrane helices in protein sequences. Proc. Int. Conf. Intell. Syst. Mol. Biol. 6:175-182.
54. Penin, F. 2003. Structural biology of hepatitis C virus. Clin. Liver Dis. 7:1-21, vii.
55. Reed, K.E., and Rice, C.M. 2000. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 242:55-84.
56. Sayle, R.A., and Milner-White, E.J. 1995. RASMOL: biomolecular graphics for all. Trends Biochem. Sci. 20:374.